Sir Gregory Winter FRS is a British pioneer of therapeutic monoclonal antibodies. He invented techniques to both humanise (1986) and, later, to fully-humanise using phage display, antibodies for therapeutic uses. Before this groundbreaking work antibodies had failed to live up to their potential because they had been derived from mice.

In 1989 Winter was a founder of Cambridge Antibody Technology, which was one of the early commercial biotech companies involved in antibody engineering. One of the most successful antibody drugs developed was HUMIRA (adalimumab), which was discovered by Cambridge Antibody Technology as D2E7 and developed and marketed by Abbott Laboratories. HUMIRA, an antibody to TNF alpha, was the world's first fully human antibody, which achieved annual sales exceeding $1bn therefore achieving blockbuster status. Cambridge Antibody Technology was acquired by Astrazeneca in 2006 for ?702m.

In 2000 Winter founded a company called Domantis to pioneer the use of domain antibodies, which use only the active portion of a full-sized antibody. Domantis was acquired by the pharmaceutical giant GlaxoSmithKline in December 2006.

In 1995, Winter won the King Faisal International Prize for Medicine (Molecular Immunology) and in 1999 the Cancer Research Institute William B. Coley Award. Winter was formerly the Joint Head of the Division of Protein and Nucleic Acid Chemistry-Biotechnology, and is Deputy Director, at the Laboratory of Molecular Biology, Cambridge, an institution funded by the UK Medical Research Council. He is also Deputy Director of the MRC?s Centre for Protein Engineering. Winter was knighted in 2004. He is a Fellow of Trinity College, University of Cambridge.